Ticagrelor: A Reversible P2Y12 Inhibitor in Preventionof Thrombotic Events

Antiplatelet drugs play a crucial role in patients of coronary artery diseases, cerebrovascular diseases, and maintaining the patency of revascularised arteries and stents after coronary angioplasty. Ticagrelor is a new, reversible inhibitor of P2Y12, a purinergic adenosine di phosphate receptor present on the surface of platelets. Ticagrelor is more potent, directly acting as it does not require conversion to active metabolite, therefore it has rapid onset and offset of action. It has greater and more predictable anti platelet action with lesser -individual variation as compared to Thinopyridine group (Clopidogrel, Ticlopidine, and Prasugrel). Clopidogrel like drugs are prodrugs and irreversible inhibitor of P2Y12 receptor. Ticagrelor is used in prevention of thrombotic events in acute coronary syndrome and stroke. It decreases mortality and major ischemic events. It has adverse effects in the form of dyspnea and risk of major and minor bleeding.